CNOT9

Across TCGA pan-cancer cohorts, CNOT9 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CNOT9 data layer compared with 29 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CNOT9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CNOT9 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where CNOT9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.950	0.349	.001	26	view →
HNSC	DFS	Median	All	0.698	1.000	.020	19	view →
PDAC	DFS	Median	All	0.241	0.459	.010	6	view →
GBM	OS	Median	All	0.607	0.460	.015	4	view →
LSCC	DFS	Median	All	0.966	0.905	.034	1	view →
CCRCC	OS	Median	All	0.689	0.919	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CNOT9–LUAD (DFS)

Open the LUAD breakdown →